Клиническая оценка эффективности использования иммуномодулятора циклоферона в лечении больных с малосимптомным течением туберкулеза легких

In patients with low-symptomatic course of pulmonary tuberculosis we revealed tolerance of adaptive systems of organism, mediated by functional insufficiency of alveolar macrophages. That has become the pathogenetic ground for application of immunomodulator cycloferon (methylglucamin acridonacetate) in treatment of these patients. This preparation can make an activating impact on the system of mononuclear phagocytes. It has been shown that application of Cycloferon in treatment of patients with low-symptomatic course of tuberculosis favours activation of sympathoadrenal system and stimulates secretion of glycocorticoids, cell branch of immunity, phagocytic function of macrophages, increases anti-inflammatory potential of an organism and improves the efficacy of treatment.